Targeting Genomics for Liver Disease Prognostics and Therapeutics
Nov
13
2023
Grand Ballroom
-
Sheraton Boston Hotel
2:00
- 3:30 PM EST
Speakers
Description
Abstracts
- DYNAMIC EVOLUTION OF CIRCULATING TUMOR DNA IN PATIENTS WITH HEPATOCELLULAR CARCINOMA ACROSS TUMOR STAGES AND TREATMENTS
- HBV VIRUS-HOST CHIMERA DNA SERVES AS A PERSONALIZED CIRCULATING BIOMARKER FOR RESIDUAL TUMORS AFTER SURGICAL RESECTION OF HEPATOCELLULAR CARCINOMA
- NOVEL SERUM METABOLOMIC SIGNATURE OF PNPLA3 HOMOZYGOSITY IN HUMAN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
- TARGETED THERAPY ADAPTED TO TUMOR BIOLOGY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA OR HEPATOCHOLANGIOCARCINOMA REFRACTORY TO ATEZOLIZUMAB/BEVACIZUMAB
- SINGLE-NUCLEI TARGETED DNA SEQUENCING REVEALS PATTERNS OF SELECTIVE CLONAL EVOLUTION DURING HEPATOCELLULAR CARCINOMA (HCC) PROGRESSION
- MULTI-ANCESTRY WHOLE GENOME SEQUENCING (WGS) AND META-ANALYSIS TO IDENTIFY LOCI ASSOCIATED WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)